Stematix

The Commercialization of Stem Cell Research

Stematix operates on the principle that regenerative medicine can be successful as a commercial medical option for a large number of patients. Since 2008, Stematix has focused on key areas in adult stem cell research that have established treatment protocols that are close to approval by regulatory bodies. Stematix works with international researchers and innovators to take their newly developed regulated products and services to the next level and prepare them for clinical use by leveraging their established relationships to help move the products into the hands of medical authorities and practitioners around the world.

This established pipeline of partnerships helps Stematix connect researchers, government agencies, doctors, and clinics to each other and fast-track the therapies for use in patients. This methodology benefits patients by speeding up the availability of adult stem cell therapies, which in turn helps provide a broader range of treatment options to those affected by diseases and illness that can be helped with regenerative medicine. Stematix believes this process is beneficial to the healthcare industry as a whole by treating people earlier in their illness and potentially avoiding more costly treatments as a disease or illness progresses.

Stematix currently has five main regenerative products at various stages in its process. Two of [Page 1104]the products are currently being marketed and available to patients, and all five of the products are well beyond the first three phases of the company’s development cycle. These treatments include Regenexx™ used for orthopedic procedures, AmnioClear™ for wound covering, Allostrome™ allogeneic stem cells for myocardial infarction treatment, Allostrome™ used for joint and cartilage repair, and Autologous myocardial infarction treatment.

...